Introduction: The effectiveness of inhaled therapies can be influenced by many factors, including the type of inhaler, which may have clinical implications. We report a real-world, multicenter, open-label, non-randomized, noninterventional study conducted by 200 pulmonologists across 200 centers in Hungary. The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler Ò , was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO).
INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent chronic respiratory diseases and leading causes of morbidity and mortality worldwide [1] . Asthma-COPD overlap (ACO) is a challenging phenotype of obstructive airway disease where patients have clinical features of both asthma and COPD [2, 3] . Despite the presence of established treatment guidelines for asthma [2] , many asthma patients still experience persistent symptoms and therefore poor disease control [4, 5] . Recent data indicate that improvement of asthma control continues to be a public health concern in the USA and Europe, as asthma is not well controlled or managed on national levels [6, 7] . Furthermore, most patients with COPD are symptomatic [8] , despite the available therapies, such as bronchodilators and inhaled corticosteroids (ICS).
Inhaled therapy is recommended as the primary route of administration for medication used to manage asthma [9] and COPD [10] . An additive effect in alleviating asthma symptoms has been demonstrated with combination therapy of budesonide (an ICS) and formoterol fumarate [a long-acting b2-adrenergic agonist (LABA)] (budesonide/formoterol) [11] . Budesonide/formoterol is also a recommended treatment alternative for patients with COPD who have a history of exacerbations [12] . In patients with ACO, treatment with low-to-moderatedose ICS is recommended with the addition of a LABA and/or long-acting muscarinic receptor antagonists where necessary [2] .
Many types of devices for delivery of inhaled drugs are available [13] . Effectiveness of the inhaler is crucial since a suboptimal inhalation technique may have clinical implications [14] ; effectiveness can be influenced by several factors, including age, gender, education, inhalation technique and type of inhaler used [15, 16] .
The Bufomix Easyhaler Ò (Orion Pharma, Espoo, Finland) is a multidose dry powder inhaler for the administration of budesonide/formoterol in combination, indicated for the treatment of adult patients with COPD and asthma, and adolescents (aged 12-17 years) with asthma [17] , approved in several European countries. The Bufomix Easyhaler Ò has demonstrated similar in vitro flow rate dependency compared with the Turbuhaler Ò , using clinically relevant air flow rates collected from patients with asthma and COPD [18] . Additionally, superior dose consistency was observed compared with the Turbuhaler Ò at different clinically relevant in vitro flow rates [19] . Therapeutic equivalence and equivalent bronchodilator efficacy have also been reported between the two inhalers [20, 21] .
Recent ). The dose and dosing regimen were agreed between the patient and their pulmonologist at the first visit. The following doses (lg/inhalation of budesonide/formoterol) were used, according to the Bufomix Easyhaler summary of product characteristics (SPC) [23, 24] : 160/4.5 in patients with asthma receiving 2 9 1 inhalations per day or patients with COPD receiving 2 9 2 inhalations per day; 320/9 in patients with asthma receiving 2 9 1 or 2 9 2 inhalations per day or patients with COPD receiving 2 9 2 inhalations per day. Patients with ACO were treated in accordance with Global Initiative for Asthma (GINA) guidelines [2] . The daily dose, per patient, was the same across the whole study period.
Demographic data, spirometry, current medication and smoking history were recorded using asthma and COPD assessment forms, completed during each visit by recruiting physicians (see supplementary material).
Patients
Patients were identified based on their attendance at routine clinical appointments at widespread centers in Hungary that met Good Clinical Practice requirements. Eligible patients were adults ([ 18 years old) with a physician-led diagnosis of asthma or COPD (according to GINA or Global Initiative for Chronic Obstructive Lung Disease therapeutic guidelines [2, 10] ) or ACO (also according to GINA guidelines) and without an exacerbation in the 4 weeks prior to enrollment. Additionally, patients whose disease could not be controlled with pre-existing therapy, whose proficiency in the usage of the previously prescribed inhaler was unsatisfactory, or who did not feel comfortable with their device, were also eligible for this study. Patients were excluded from the study if they had a hypersensitivity to budesonide, formoterol or lactose or if they were pregnant or breastfeeding [16] . The study was approved by the National Scientific and Research Ethics Committee of Hungary.
All procedures were performed in accordance with the ethical standards of the National Scientific and Research Ethics Committee of Hungary (the study was approved by this body) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study prior to study commencement.
End Points and Assessments
Primary outcomes were change in patient-reported outcome (PRO) measures after 12 weeks of treatment; PRO measures were assessed using the following co-primary end points: the Asthma Control Test (ACT) [25] , mini-Asthma Quality of Life Questionnaire (mini AQLQ) [26] , COPD Assessment Test (CAT) [27] and modified Medical Research Council dyspnea scale (mMRC) [28] . All other outcomes were assessed as secondary end points.
Disease control was assessed during each visit using either the ACT (ACT score B 19 indicates poorly or not well controlled asthma) or the CAT (CAT score of [ 20 indicates a high impact of COPD on their daily life); health-related quality of life (HRQoL) measures were assessed using the mini-AQLQ (mini-AQLQ score \ 4 indicates very limited daily life due to asthma) and the mMRC (mMRC score [ 1 indicates difficulty in walking due to breathlessness).
To evaluate the usage of a previous inhaler (if it existed) and the Bufomix Easyhaler Ò in everyday life, patients received a previously validated questionnaire (e.g., how easy was it to learn, use, clean and inhale from the inhaler, how much the inhaler use helped in everyday activities such as sports, walking, etc., and patients' perception/preference for their inhaler) [29] . This self-assessment was completed during all visits (Table 1) . Additionally, patient satisfaction using a previous inhaler (if it existed) or the Bufomix Easyhaler Ò was analyzed at visit one using closed questions scored on a six-point scale: one (very good) to six (unsatisfactory). Before the start of the study, participating pulmonologists were trained in how to use the Bufomix Easyhaler Ò by Orion Pharma staff; physicians then showed individual patients how to handle the device at the first visit, according to the SPC [23, 24] . After training the patient in using the Bufomix Easyhaler Ò , physicians were asked to assess the ease of use (through visits 1-3) and the time taken to teach the patient how to use the device (at visit 1) (Table S1 ). For patients whose disease could not be controlled with pre-existing therapy, or whose proficiency in the usage of their previous inhaler was unsatisfactory, pulmonologists assessed the use of the previous device by asking the same questions provided for the Bufomix Easyhaler Ò . Forced expiratory volume in 1 s (FEV 1 ) was determined using spirometry through visits 1-3 (measured as a pre-bronchodilator assessment), according to the American Thoracic Society/ European Respiratory Society task force guidelines [30, 31] and expressed as FEV 1 % predicted normal.
Statistical Analyses
All data were expressed as percentages or means with standard deviations. The Wilcoxon's signed rank test was used to compare change from baseline; p \ 0.05 was considered statistically significant. No power calculations were performed because of the real-world nature of the study.
All questionnaires were provided in e-format case report forms (CRFs) by VIT Ltd., Hungary; scores were input into these CRFs by the pulmonologist at each visit after they read each question to the patient.
All statistical analyses were performed using SAS Ò software, version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).
RESULTS

Baseline Patient Characteristics
Overall, 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99). Baseline characteristics are summarized in Table 2 . Patients with asthma were younger, with a mean age of 53.2 years [standard deviation (SD), 16.3] , than those with COPD (mean age 64.1 years; SD, 9.9) and ACO (mean age 61.9 years; SD 10.6). (Fig. S1 ). At baseline, most of the 1498 participants had poorly controlled asthma or experienced a high impact of COPD on their daily life. Accordingly, 398 (64.1%) patients with asthma, 563 (72.4%) patients with COPD and 82 (82.8%) patients with ACO were using a maintenance medication at baseline.
Effect of Bufomix
Patients with asthma had a mean (SD) ACT score of 14.2 (4.1) at baseline; disease control was significantly improved by visit 3 (p \ 0.001), when the mean (SD) ACT score was 21.0 (2.7). By visit 3, 73.2% of all patients with asthma (asthma and ACO) had 'well-controlled' disease (Fig. 1a) . Furthermore, a marked reduction in reliever inhaler use was observed at visit 3; 87.2% of all patients with asthma reportedly used their reliever inhaler no more than once a week compared with 32.2% of patients at visit 1 (Fig. 2) .
Patients with COPD had a mean (SD) CAT score of 24.2 (5.7) at baseline. Disease control was significantly improved by visit 3 (p \ 0.001) when the mean (SD) CAT score was 18.2 (5.1). By visit 3, 67.7% of all COPD patients (COPD and ACO) experienced low-medium disease impact on their QoL (CAT B 20; Fig. 1b) .
Overall, twelve weeks of treatment with the Bufomix Easyhaler Ò resulted in a significant improvement in lung function (FEV 1 % predicted). In total, mean (SD) FEV 1 % predicted increased from 62.2% (21.8) at baseline to 69.9% (23.1) at visit 3 (p \ 0.001). Similar improvements in lung function were observed in all patient groups; patients with asthma, COPD and ACO (Tables 3, 4 ). Most importantly, significant improvement in lung function was 
Effect of Bufomix Easyhaler Ò on Healthrelated Quality of Life
Patients with asthma had a mean (SD) mini-AQLQ score of 3.8 (0.9) at baseline, indicating a moderate impairment of QoL from asthma. A significant improvement in mini-AQLQ score, indicating some impairment, was observed by visit 3 [5.2 (0.7); p \ 0.001] ( Table 3) .
Patients with COPD had a mean (SD) mMRC score of 1.9 (0.9) at baseline, indicating that most patients walk more slowly than people of the same age because of breathlessness or must stop for breath when walking at their own pace. A significant improvement in the mMRC score was observed by visit 3 [1.2 (0.8); p \ 0.001] (Table 4) .
Patient Satisfaction with the Use of Bufomix Easyhaler Ò and Physicians' Assessments
Patients were asked to describe their perceptions of different attributes of their current treatment from the multiple-choice questions (Table 1) . Overall, patient satisfaction was higher for the Bufomix Easyhaler Ò than for the other inhalers (Fig. 3) . Furthermore, more than 90.0% of physicians described the Bufomix Easyhaler Ò as easy to teach, with 98.9% of their patients having learned the technique within 10 min and 73.8% within 5 min of teaching (Fig. 4) .
DISCUSSION
We present the first real-world PRO data collected from patients with obstructive airway disease using the Bufomix Easyhaler , may obtain wellcontrolled disease or complete control (ACT score 20-25; CAT score \ 20) when treated in a real-world study setting. Roughly 3 months after switching to the Bufomix Easyhaler Ò , patients had improved lung function, and all groups (including patients who switched from another device to the Bufomix Easyhaler Ò ) showed significant improvement in the quality of life in all parameters assessed. No adverse events were reported by the participating physicians, supporting the safety profile of Bufomix Easyhaler Ò formulations for patients with obstructive airway disease.
Overall, patients considered the Bufomix Easyhaler Ò as portable, easy to use and easy to keep clean during daily activities. This statement is supported by the continued use of the Bufomix Easyhaler Ò throughout the study, with no discontinuations reported. Furthermore, study physicians reported that use of the Bufomix Easyhaler Ò was easy to teach, with their patients learning inhaler use quickly. Our data support previous patient preference data (based on studies in children and adults) that demonstrated the Easyhaler Ò was easy to teach, learn and use, coupled with more user satisfaction [18, 32] ; findings were recently confirmed by a meta-analysis [19] .
The Bufomix Easyhaler Ò achieved well-controlled disease or complete disease control despite a high proportion of patients being smokers. Patients were satisfied with the therapy, and the Easyhaler Ò was easy for them to use. Most of our patient population had primary or high school education; therefore, it is likely that ease of use and adequate training on how to use the inhaler were important in ensuring [14] .
Our study provides real-world data using a large representative sample of Hungarian patients using the Bufomix Easyhaler Ò in everyday clinical practice. Although the analyses were robust and performed using verified questionnaires, the study has limitations. The study was an open-label, non-parallel design study with no comparator devices, and the ACO asthma-COPD overlap, ACT asthma control test, CAT COPD assessment test, COPD chronic obstructive pulmonary disease study population may have biased the assessment of patient preferences for inhaler device, as only patients who were uncontrolled and therefore likely to have been unsatisfied with their previous inhaler were evaluated. Furthermore, data on patient adherence and productspecific training for previous inhalers were unavailable for inclusion. Conclusions on the effectiveness of the Bufomix Easyhaler Ò are also limited by the lack of exacerbation data for patients with asthma and COPD and direct comparisons between inhalers.
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